PQR626
Modify Date: 2024-01-09 11:19:41
PQR626 structure
|
Common Name | PQR626 | ||
|---|---|---|---|---|
| CAS Number | 1927857-98-4 | Molecular Weight | 435.47 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C20H27F2N7O2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of PQR626mTOR inhibitor-7 is an orally available, and brain-penetrant mTOR inhibitor extracted from patent WO2017198346A1, compound example 44, has an IC50 of 5 nM for mTOR. mTOR inhibitor-7 can be used for the research of neurological disorder[1]. |
| Name | mTOR inhibitor-7 |
|---|
| Description | mTOR inhibitor-7 is an orally available, and brain-penetrant mTOR inhibitor extracted from patent WO2017198346A1, compound example 44, has an IC50 of 5 nM for mTOR. mTOR inhibitor-7 can be used for the research of neurological disorder[1]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 5 nM (mTOR)[1] |
| In Vitro | mTOR inhibitor-7 (0.04-5 μΜ; 1 hour) has IC50s of 197 nM and 87 nM for pPKB S473 and pS6 S235/S236, respectively, in-cell western blot. S6 kinase (S6K), S6 ribosomal protein (S6rP) and 4E-binding protein (4E-BP) are prominent downstream effectors of mTOR[1]. Western Blot Analysis[1] Cell Line: A2058 cells Concentration: 0.04 μΜ, 0.08 μΜ, 0.155 μΜ, 0.3125 μΜ, 0.625 μΜ, 1.25 μΜ, 5 μΜ Incubation Time: 1 hour Result: Inhibited mTOR in cell. |
| References |
[1]. Denise RAGEOT, et al. Treatment of neurological disorders. WO2017198346A1. |
| Molecular Formula | C20H27F2N7O2 |
|---|---|
| Molecular Weight | 435.47 |